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Abstract
Background. Lymphoedema is an accumulation of protein-rich fluid in the interstitial space. Long-lasting
lymphoedema leads to chronic inflammation, fibrosis and tissue damage. Lymphoedema seriously affects a
patient's body image, daily activities and mobility. At present, there is no curative treatment: the aim of
lymphoedema management is long-term symptom control and an improvement in the health-related quality
of life (HRQoL).
Aim. The aim of this study was to assess the following: — the effect of complex decongestive therapy (CDT)
on the quality of life of lymphoedema patients; — the effect of CDT on clinical symptom relief; — changes in
HRQoL domains as defined in the SF-12 questionnaire.
Methods. 30 patients were enrolled into a treatment group in a Lymphoedema Clinic. We assessed physical
symptoms such as pain, heaviness, mobility, the fitting of clothes and body presentation at the beginning of the
study, again after two weeks of intensive treatment and then after 4 months of maintenance therapy. Patients
completed the SF-12 questionnaire at the beginning and at the end of the study.
Results. The research revealed that complex intensive therapy significantly improves both physical and
mental aspects of HRQoL. No correlation between HRQoL improvement and limb volume reduction has been
found. CDT and the intensive phase of treatment in particular improved the fit of clothes and limb presenta-
tion, relieved pain and heaviness, and also improved limb mobility.
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Introduction
Lymphoedema
Chronic lymphoedema is the accumulation of
excess protein-rich fluid in the interstitial tissue. Its
long-lasting presence leads to the occurrence of the
inflammation process, resulting in damage to the
tissue affected by lymphoedema [1]. The range of
people suffering from the disease is diverse, includ-
ing patients with primary oedema, caused by devel-
opmental anomalies of the lymphatic system, as
well as a wide group of patients with secondary
oedema, usually associated with therapy and/or pro-
gression of neoplastic disease, inflammation chang-
es in the course of systemic diseases, bacterial in-
fections and injuries.
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Due to the lack of a satisfactory method of caus-
al therapy, the treatment which combines lymphat-
ic drainage, the use of compression garments, exer-
cise and proper skin care, i.e. complex decongestive
therapy (CDT), is considered to be the most effec-
tive treatment.
Lymphoedema, as a chronic and progressive dis-
ease which can only be treated symptomatically,
has a strong influence on a patient's quality of life.
Patients complain of pain, altered body image and
the difficulties in social contact resulting from this.
Quality of life
In the last twenty years, interest in the problem
of health-related quality of life (HRQoL) has in-
creased significantly. The reason for this is the tak-
ing into consideration of the patient's subjective
evaluation of his/her own health as a sign of the
holistic approach to the therapy process.  The no-
tion of quality of life is very broad and comprises
all those realms of the human condition which are
significant for that person.  HRQoL is a narrower
notion and can be defined as the patient's subjec-
tive evaluation of the condition of his or her own
health. The measurement of the general HRQoL
consists of the assessment of the patient's capaci-
ty for everyday physical, psychological and social
activity [2]. The tools for the measurement of HRQoL
should be characterized by the following psycho-
metric criteria:
— reliability: the tool should be free from measure-
ment errors;
— accuracy of the range the tool is required to
measure;
— sensitivity: the capacity for registering changes
occurring over time [3].
There are two types of tool for HRQoL evalua-
tion: general and specific for a given disease. Gen-
eral tools focus on the main components of the
quality of life and can be used in examining pa-
tients with various health conditions and suffering
from different diseases. Specific tools, in turn, are
designed for examining specific groups of patients.
At present, it is thought that the assessment of the
quality of life should become a routine component
of all examination procedures.
In clinical research carried out on various groups
of patients, the negative effect of chronic lymphoe-
dema on their quality of life has been proved un-
questionably.
While assessing various realms of the quality of
life with the use of tools meeting psychometric cri-
teria, the most significant deterioration has been
found in the fields of the perception of the patient's
own body, concerns for the future, and the effect of
the physical condition on the performance of every-
day tasks [4]. Patients with chronic lymphoedema
declare pain problems much more often and their
psychological condition has a negative effect on
their everyday performance [5]. Other research has
shown a deterioration in physical efficiency and so-
cial activity [6]. Patients suffering from lymphoede-
ma following a mastectomy have more difficulties
in adapting to their new health situation and de-
scribe a more significant deterioration of the func-
tion of a limb than patients after a mastectomy but
without lymphoedema [7].
Other research, carried out with non-standard-
ized tools, has shown that patients with chronic
lymphoedema are more often affected by feelings
of fear, depression, difficulties in contacts with part-
ners, workmates and in social encounters [8], aban-
don their hobbies much more often and seek psy-
chological help [9, 10].
The aim of the study
The aim of the study was the assessment of the
following:
— complex decongestive therapy (CDT) and its ef-
fect on the quality of life for patients with chronic
lymphoedema, measured by the SF-12 test;
— the effect of CDT on the clinical symptoms felt
by patients;
— the most significant changes in patients' realms
of life as defined in the SF-12 test.
The research project has been approved by the
Bioethical Commission of The Poznań University of
Medical Sciences. A licence for the use of the SF-12
questionnaire in clinical research has been obtained.
Material
Thirty women with chronic lymphoedema of var-
ious etiologies, aged 32–71 (average age of the
subjects was 56.8 ± 8.99 years) qualified for the
research. The subjects were patients of the Lym-
phoedema Therapy Outpatient Clinic. Each of them
had been informed of the purpose and character of
the research and had given written permission for it
to be conducted. The patients had been informed
that the data contained in the SF-12 questionnaire
would be used only as part of the cognitive study
and would remain anonymous.
The people who qualified for the research had
sufficient circulation, properly functioning kidneys
and liver, and had no features of active neoplastic
disease or deep vein thrombosis. Four subjects had
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been diagnosed with diabetes, treated with oral
medication; 13 subjects were taking hypotensive
medication and had appropriate blood pressure; in
2 subjects' medical history, hypothyreosis had been
diagnosed and was treated with hormone substitu-
tion during the research.
The diagnosis of lymphoedema was made on the
basis of the interview, physical examination, basic
laboratory examination and lymphoscantiscanning.
Twenty-two of the patients (73.33%) had upper
limb oedema (of which only one was bilateral), while
8 (26.66%) had symptoms of lymphoedema in the
lower limbs (4 of them bilateral).
In 22 patients (73.33%), secondary lymphoe-
dema was diagnosed: in 9 it had been caused by a
mastectomy, in 11 by a mastectomy with consecu-
tive radiotherapy, in 1 it was the effect of past
erysipelas, while 1 patient had undergone irradia-
tion of the superclavicular lymph nodes due to lym-
phogranulomatosis maligna. The group of patients
with primary oedema consisted of 8 people
(26.66%). In all of them, the first symptoms of the
disease occurred in adolescence but only 3 had
positive family history.
According to the classification of the British Lym-
phology Society (www.lymphoedema.org/bls) (Ta-
ble 1) the patients who qualified for the research
suffered from mild, uncomplicated (6 people, 20%)
or severe, complicated (24 people, 80%) forms of
lymphoedema.
The characteristics of the researched group are
presented in Table 2.
The average duration of the disease was 111
months (± 143.81 months). The majority of the re-
search group (25 people, 83.3%) had never received
therapy before, 4 people had temporarily had mas-
sages with the use of pneumatic pumps, which had
not produced sufficient effects, while one person had
undergone a debulking operation (whose type has
not been established, as the patient has lost the
documents concerning the hospitalization).
The starting volume of the oedematous limb  was
2976.20 ml (± 104.43). In the group of patients
with unilateral alterations the average volume of
Table 1.  Clinical classification of chronic lymphoedema
according to The British Lymphology Society
Mild Severe
Normal shape Distorted limb shape
Intact healthy skin Abnormal skin
Subcutaneous tissue Subcutaneous tissue
soft and pitted non-pitted
Excess limb volume < 20% Excess limb volume > 20%
the oedema was 878.92ml (± 383.31), which
amounted to 41.92% (±18.83).
The symptoms which prompted the patients to
pay a visit to the clinic were, first of all, worrying
alterations in the appearance of their limbs (23 peo-
ple); the feeling of heaviness of the limb(s) (22 peo-
ple); difficulties with garments fitting (16); pain (11);
and mobility limitation (8). The diversity of the symp-
toms declared by the patients in subgroups of clini-
cal and etiological classification is presented respec-
tively in Tables 4 and 5. In the medical history, com-
plications in the form of acute inflammatory episodes
of subcutaneous tissue were found in 19 patients,
out of which 6 had experienced it more than 5 times.
Methods
General outline
The patients who agreed to take part in the re-
search were obliged to remain under the control of
the Lymphoedema Therapy Outpatient Clinic of the
Chair and Department of Palliative Medicine in the
Poznań University of Medical Sciences for the peri-
od of 4 months from the beginning of the therapy.
The first visit involved the initial qualification on
the basis of the interview and physical examination.
During the visit, the following examinations were
also carried out:
— the taking of blood for routine laboratory tests:
morphology, creatinine, glucose, electrolytes,
AspAt, AlAt, bilirubin, electrophoresis;
— the measurement of limb volume;
— an assessment of blood flow in the lymphoe-
dematous limb in order to exclude the possibili-
ty of the coexistence of fresh deep vein throm-
bosis;
— lymphoscantiscanning in order to confirm the
diagnosis and define the stage of disease ad-
vancement.
During the first visit the patient also completed
the questionnaire for life quality assessment (SF-12).
After receiving the results of the image tests the
patient began the complex decongestive therapy.
The period of intensive therapy lasted for 2 weeks.
The patients came to the clinic every day between
9.00 am and 12.00 noon and were subjected to
lymphatic drainage and multilayer bandaging ac-
cording to generally accepted rules. The following
materials were used for the bandaging:  on skin, a
non-stretch cotton sleeve; on fingers or toes, gauze
bandages of high elasticity (Matolast), then a syn-
thetic undercoat of padding (Matoban) externally
and short-stretch elastic bandages (Matopres). At
home, the patients were asked to perform the rec-
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Table 2. Characteristics of the research group
Patient Age Limb Type of Clinical Time
lymphoedema classification
EA 67 Upper Secondary Severe 4 years
MT 45 Lower (both) Primary Mild 18 years
JZ 51 Upper Secondary Severe 10 years
HM 55 Upper Secondary Severe 1 year
EK 50 Upper Secondary Severe 4 months
BK 45 Lower (both) Primary Severe 30 years
HC 67 Lower Primary Severe 10 years
WB 54 Upper Secondary Severe 2 years
ME 52 Lower Primary Severe 20 years
UM 64 Upper Secondary Severe 14 years
HR 62 Upper Secondary Severe 7 years
IR 68 Upper Secondary Severe 6 years
KM 70 Upper Secondary Severe 14 years
DP 50 Upper Secondary Severe 6 years
BW 63 Upper Secondary Mild 1.5 months
BS 65 Upper Secondary Severe 6 months
MM 62 Upper Secondary Mild 4 months
IM 52 Upper Secondary Severe 6 years
HB 57 Upper Secondary Severe 2 years
BG 71 Upper Secondary Severe 6 years
IP 67 Upper Secondary Severe 6 months
BB 58 Upper Secondary Severe 3 months
IM 63 Upper Secondary Mild 6 months
DS 53 Upper Secondary Severe 12 years
PW 55 Lower (both) Primary Severe 8 years
DN 54 Upper (both) Primary Severe 45 years
GK 54 Lower (both) Primary Severe 45 years
KK 54 Upper Secondary Severe 1 year
MW 44 Lower Secondary Mild 5 months
RS 32 Lower Primary Mild 3 years
ommended exercises and wear the bandages until
the following morning, taking them off no earlier
than 2 hours before the next planned visit. At week-
ends, the subjects of the research were left without
compression bandages.
During the intensive therapy the patients were
instructed on proper skin care of the oedematous
limb(s) and taught to carry out simple lymphatic
drainage at home. The second visit took place after
the end of the intensive therapy and consisted of
the following:
— an evaluation of the clinical symptoms in a 4-
step range, where 0 meant lack of improvement,
1 — slight improvement, 2 — significant im-
provement, 4 — condition having been like that
before the disease;
— a physical examination;
— the measurement of limb volume;
— the fitting of compression garments.
The third visit took place two weeks after the
end of the intensive therapy and consisted of:
— a physical examination;
— the measurement of limb volume.
Successive visits took place at one-month inter-
vals. Generally, each patient made 6 visits to the
clinic during the period of the research. During the
visit which ended the 4-month observation period,
the patient was again asked to complete the quali-
ty of life questionnaire SF-12 and perform a self-
evaluation of clinical symptoms.
The method of assessing quality of life with
the use of the SF-12 questionnaire
The SF-12 questionnaire is an original test, cre-
ated for the purpose of assessing health-related
quality of life. The SF-12 meets all the psychomet-
ric criteria (of reliability, accuracy and sensitivity)
and can be used for the assessment of HRQoL both
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in large populations and in the small groups in-
cluded in clinical research [11]. The test assesses
eight HRQoL components: general health condi-
tion, physical efficiency, effect of the psychologi-
cal and physical condition on everyday activities,
mood, energy, pain and social performance. The
patient does not need much time to complete the
questionnaire and can do this during the visit to
the clinic. The brevity of the form is undoubtedly
an advantage of  the SF-12, especially as the pa-
tient has to answer the questions several times
during the examination.
The patients were given the test for independent
completion during their first and last visits to the
clinic. The answers were evaluated according to the
key in the number and the percentage scales. The
higher the score, the better the HRQoL assessment.
Statistical analysis
The data obtained were subjected to statistical
analysis, the purpose of which was to examine the
significance of the differences and the relationships
between the features. The research used a Student's
t-test and the ANOVA one-factor variance analysis
for features whose spread agreed with the normal
distribution, or the Mann-Whitney and Kruskal-Wal-
lis tests for those which lacked such agreement.
The examination of volume changes over time
was tested with the use of ANOVA variance analysis
in the system with repeated measurements.
The relationship between features was analyzed
with the use of the Pearson correlation coefficient
for features in agreement with the normal distribu-
tion, or the Spearman correlation coefficient for
those without such agreement.
Results
Limb volume
During the 4-month observation period an
average limb volume reduction (Vmed) of 329 ml
(± 226.50 ml) was achieved. The limb volume
change obtained during the intensive therapy (i.e.
between measurements 1 and 2 and  successive
ones) was statistically significant (p < 0.0001***),
while further volume reduction obtained during the
maintenance therapy (i.e. between measurements
2 and 3 and successive ones) was not (p > 0.05).
The alterations in Vmed over time are shown in
Table 3.
In the group of patients with unilateral alter-
ations, the calculated average oedema volume
(DVmed) was 878.92ml ( ± 383.31), which amounts
to 41.92% ( ± 18.83) (DVmed%). After the 4-month
therapy period, those values amounted to 503.36ml
(±331.54) and 23.67% (±15.00).
The dynamics of alterations over time of the
DVmed and DVmed% parameters are shown respec-
tively in Tables 4 and 5.
The quality of life assessment with the use
of the SF-12 questionnaire
During the CDT period an improvement in the
patients' quality of life was achieved (p < 0.0001***).
Table 3. Changes in the Vmed value in consecutive measurements
Measurements Vmed  [ml] SD –95.00% + 95.00%
1. 2967.2 04.43 2763.4 3188.9
2. 2713.7 99.86 2510.3 2917.1
3. 2697.9 109.44 2475.0 2920.9
4. 2681.0 108.49 2460.0 2902.0
5. 2655.4 122.40 2406.1 2904.7
6. 2638.7 10,4,83 2425.2 2852.2
Table 4. DVmed in consecutive measurements
Measure- Measured DVmed Mean Minimum Maximum SD
ment limbs   [ml]
1. 25 878.92 770.00 402.00 1672.00 383.31
2. 25 599.84 605.00 130.00 1334.00 320.12
3. 25 546.96 525.00 70.00 1244.00 335.78
4. 25 543.20 533.00 16.00 1319.00 372.13
5. 25 545.48 449.00 37.00 1609.00 407.02
6. 25 503.36 432.00 25.00 1152.00 331.54
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The change was observed both in the general HRQoL
and in its components covered by the SF-12 ques-
tionnaire. The differences between the starting as-
sessment and that made at the end of the 4-month
observation period were statistically significant for
all HRQoL components. The changes in the value of
general life quality and its specific aspects in the
grade and the percentage scales are shown in Tables
6 and 7, while the p coefficient values for specific
HRQoL realms are shown in Table 8.
No correlation was observed between the extent
of Vmed and DVmed wzgl [%] (relative average) and
the extent of HRQoL improvement (p > 0.05). For
specific HRQoL components, in turn, the degree of
limb volume reduction correlated only with the im-
provement within the realm of the influence of the
psychological condition on everyday performance
(p < 0.05).
While analyzing the extent of HRQoL improve-
ment in patients with similar levels in the reduction
of clinical symptoms, no statistically significant dif-
ferences were observed for any of the assessed symp-
toms (p > 0.05).
 The scale of the relief of clinical symptoms
Within the 4-month therapy period, the relief of
clinical symptoms was observed. While evaluating the
influence of the entire therapy on the relief of clinical
Table 5. DVmed [%] in consecutive measurements
Measure- Measured DVmed Mean Minimum Maximum SD
ment limbs   [ml]
1. 25 41.92 37.00 20.00 76.00 18.83
2. 25 28.26 26.00 5.00 57.00 14.74
3. 25 24.94 25.00 3.00 60.00 14.25
4. 25 25.38 24.00 0.50 65.00 17.41
5. 25 24.56 22.00 1.00 57.00 15.59
6. 25 23.67 23.00 1.00 57.00 15.00
Table 6. The p coefficient values for specific HRQoL
components
HRQoL Domains p
Physical role 0.000012
Physical functioning 0.000050
Bodily pain 0.000463
Social functioning 0.001944
Mental health 0.003286
General health 0.007686
Vitality 0.010788
Emotional role 0.017818
HRQoL (in general) 0.000003
HRQoL — health-related quality of life
symptoms, significant improvement was observed for
all the symptoms evaluated. At specific stages of the
therapy, the following results were obtained:
— after the period of intensive therapy, there was
a significant improvement in the patients' eval-
uation of all symptoms except mobility;
— further therapy did not bring statistically im-
portant changes to the evaluation of the clini-
cal symptoms.
The differences in the evaluation of clinical
symptoms during specific stages of the therapy
and after 4 months of observation are shown in
Table 7.
Discussion
Quality of life
The answers to the SF-12 questionnaire, com-
pleted by the patients before and after the 4 months
Table 7. The assessment of the relief of clinical symp-
toms
Clinical symptoms p
Body perception
After the intensive phase < 0,01**
After the maintenance phase > 0.05 (NS)
After 4 months < 0.001***
Heaviness
After the intensive phase < 0.001***
After the maintenance phase > 0.05 (NS)
After 4 months < 0.001***
The fit of clothes
After the intensive phase < 0.01**
After the maintenance phase > 0.05 (NS)
After 4 months < 0.001***
Pain
After the intensive phase < 0.05*
After the maintenance phase > 0.05 (NS)
After 4 months < 0.001***
Mobility
After the intensive phase > 0.05 (NS)
After the maintenance phase > 0.05 (NS)
After 4 months < 0.01**
NS — non significant
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of therapy, showed a statistically significant im-
provement in the evaluation of HRQoL (0.0001***)
and all its components. The analysis of the changes
in the evaluation of the HRQoL domains showed
that the biggest change took place in that of the
effect of physical condition on everyday perfor-
mance. The most significant improvement was ob-
served in the physical aspects.
No link was observed between the degree of
limb volume reduction and the change in HRQoL,
which indicates that the improvement in HRQoL felt
by the patients is independent of oedema volume
reduction. Similarly, no link was observed between
HRQoL improvement and the degree of the relief of
all assessed clinical symptoms.
So far, there have not been many references in
the literature concerning the problem of life quality
for patients treated for chronic lymphoedema. The
few existing reports, however, show a positive in-
fluence of complex decongestive therapy on patients'
quality of life and its specific realms.
Stizia and Sorbido [12] assessed the effect of
CDT on the quality of life for patients suffering
from lymphoedema in the course of various malig-
nancies. The research group consisted of 34 pa-
tients and the research tool was the Nottingham
Health Profile (NHP) questionnaire. In addition, the
authors used a 9-grade scale of skin condition eval-
uation, known as the Skin Index. The research
showed an improvement in the general quality of
life, most significantly in the field of general fit-
ness. No correlation, however, was observed be-
tween limb volume reduction and a change in any
NHP domain except pain. It was also observed that
an improvement in HRQoL correlates with an im-
provement in skin condition, assessed by means of
the Skin Index.
Mirolo et al [13] assessed the change of life qual-
ity during CDT using the “Functional Living Index
— Cancer”. During the intensive treatment and con-
secutive maintenance therapy, a slight but statisti-
cally significant improvement in the quality of life
was observed.  No correlation, however, was ob-
served between the quality of life improvement and
lymphoedema reduction.
Williams [14] in his quoted work also evaluated
patients' quality of life, using the EORTC QLQ-30
questionnaire. The research showed that only after
the lymphatic drainage period was there a statisti-
cally significant improvement in the quality of life,
especially in its emotional aspects. The research did
not define the coefficient of correlation between
limb volume reduction and the change in quality of
life and its specific domains.
Pain et al [15] examined the effect of oedema
size and limb mobility, assessed by objective tools,
on HRQoL for 48 patients with lymphoedema fol-
lowing a mastectomy. The quality of life was evalu-
ated by means of the SF-36 questionnaire.  The
researchers observed a decidedly worse assessment
in the domains describing mobility and pain in the
research group in comparison with respective val-
ues in the general population. The degree of limb
efficiency in objective measurements correlated with
the mobility evaluation in SF-36. For oedema vol-
ume in turn, no such relationship was observed. It
may, therefore, be indirectly concluded that limb
mobility means more for the improvement of life
quality for patients with lymphoedema than limb
volume.
From the above quoted sources we can conclude
that patients who are treated with CDT experience
an improvement in the quality of life.
It is very difficult to carry out a comparative anal-
ysis of the research conducted so far. While limb
volume was measured in the same way in all of the
research, the scheme for conducting the therapy,
its duration, as well as the groups of patients par-
ticipating, were all very different. In addition, a dif-
ferent tool for assessing the quality of life was used
in each piece of research, which also restricts the
possibilities of comparative interpretation. In spite
of this, it seems significant that in all the studies,
regardless of the differences between them, life
quality assessment improved as a result of the treat-
ment.
Another analyzed problem is the identification
of factors affecting the extent of HRQoL improve-
ment. The factors listed most often in the referenc-
es are the degree of limb volume reduction, the
level of experienced pain, limb efficiency assessment
and skin condition.
In the research covered by this study, no connec-
tion was observed between HRQoL improvement
and volume reduction or the degree of relief of clin-
ical symptoms.  In the works quoted by the author,
a relationship between HRQoL and the level of ex-
perienced pain, limb efficiency and skin condition
was observed.  No such relationship was observed
for limb volume reduction. It is, therefore, possible
that limb volume measurement, HRQoL value and
the scale of evaluating clinical symptoms are inde-
pendent indices of treatment efficiency.
The extent of the relief of clinical symptoms
Along with the alteration in limb volume, clini-
cal symptoms subsided during the treatment. After
the 4-month therapy, patients reported the signifi-
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cant relief of such ailments as negative changes in
appearance, difficulties with clothes fitting, the feel-
ing of limb heaviness, pain and limited mobility.
However, the most important for the relief of symp-
toms of the illness was the intensive therapy, as
after that period of treatment a significant positive
change was felt by patients in all aspects except
limb mobility. In turn, further therapy did not bring
statistically significant changes in the evaluation of
symptoms.
The perceived pain level, changes in the patient's
own body image and the degree of limb mobility
deficiency are considered subjective indexes/indices
of the effectiveness of lymphoedema treatment [16].
So far, there has been no standardized tool which
would assess the level of the symptoms characteris-
tic of a patient with chronic lymphoedema. For that
reason, some of the authors included, as a comple-
mentary tool, the evaluation of clinical symptoms
made by the patient on the basis of a method de-
veloped for specific research.
While assessing the effect of the therapy on the
symptoms reported by the patients, Woods [4] ob-
served an improvement in the perception of a pa-
tient's own body (46% of the subjects), the fit of
clothes (65%), and limb mobility (43%). The research
group consisted of 37 women who had had a mas-
tectomy and who had been treated for lymphoede-
ma for at least 6 months. The therapeutic schemes
used were not uniform for the whole group of pa-
tients.
Hardy and Taylor [17] examined a group of 219
patients suffering from lymphoedema of various
etiologies: 144 patients qualified for intensive ther-
apy, while the others, with smaller alterations , be-
gan the therapy at the maintenance stage. The re-
searchers observed that after treatment patients
reported less pain, had fewer difficulties with clothes
fitting, improved limb mobility, and a lower level of
frustration and fear. The study does not contain the
assessment of clinical symptoms at specific stages
of the treatment.
Williams [14] compared the efficiency of lym-
phatic drainage and self-massage in a group of 37
women with lymphoedema following a mastecto-
my. He concluded that the drainage, which is an
integral part of the intensive treatment stage, has
a decidedly bigger influence than self-massage on
the relief of clinical symptoms, such as pain, dis-
comfort, the feeling of heaviness, fullness, burst-
ing and stinging. However, the research value of
the works assessing specific CDT elements is con-
troversial [18].
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